Lowe is the VP, of Commercial Operations at Eyenovia, and discussed the FDA approval of MydCombi for mydriasis at the 2023 ASCRS annual meeting in San Diego.
Norbert Lowe VP, of Commercial Operations from Eyenovia discussed the FDA approval of MydCombi for mydriasis at the 2023 ASCRS annual meeting in San Diego.
Editor’s note: Transcript lightly edited for clarity.
Hello, from ASCRS here in San Diego. I'm Norbert Lowe, vice president, commercial with Eyenovia, and we're ecstatic to announce the first approval of our first commercial product, MydCombi for mydriasis. MydCombi contains two of the most common dilating drops into a fixed-dose combination, 1% tropicamide and 2.5% phenylephrine, and our proprietary Optejet microdose array print technology. This will be the first and only FDA-approved, fixed-dose combination ophthalmic spray for mydriasis.
So instead of taking two to three eyedrops for an eye exam, the medication will gently mist into the patient's eyes. How this works is the technician will press this button on the top, you'll see the blue light turn on, you point that at the patient, the patient will look at the blue light, the technician will just press this button in the back, and the medication will gently mist into the patient's eyes.
So it's easy to use. It's precise dosing. You get effective results with less medication and then potentially save the chair time in the physician offices. So we look forward to bringing this novel technology to the clinic soon.